Antibiotics specialist Xellia plots 247 layoffs on the heels of Ohio plant sale to Hikma

Following last week’s news that generic drugmaker Hikma is acquiring parts of Xellia’s assets in the U.S., the Danish drugmaker has unveiled plans for a fresh round of layoffs.

In connection with the sale of the company’s Bedford plant on the outskirts of Cleveland, Ohio, to Hikma, Xellia said it’s cutting 247 positions in the U.S. Of the affected staffers, 214 work at the Bedford facility, Xellia said in a Worker Adjustment and Retraining Notification (WARN) alert sent to the state.